Valuation: AstraZeneca PLC

Market Cap 259B 222B 207B 190B 356B 24,758B 361B 2,450B 956B 12,437B 972B 950B 41,136B P/E 2026 *
21.4x
P/E 2027 * 18.6x
Enterprise Value 278B 238B 223B 204B 383B 26,607B 388B 2,633B 1,027B 13,366B 1,044B 1,021B 44,209B EV / Sales 2026 *
4.4x
EV / Sales 2027 * 4.05x
Free-Float
96.63%
Yield 2026 *
1.99%
Yield 2027 * 2.11%
1 day+1.09%
1 week+6.59%
Current month-3.07%
1 month-4.31%
3 months-10.01%
6 months-15.53%
Current year-7.40%
1 week 1,479
Extreme 1479
1,579
1 month 1,467
Extreme 1467
1,699
Current year 1,467
Extreme 1467
1,925.5
1 year 1,365
Extreme 1365
1,925.5
3 years 1,226
Extreme 1226
1,925.5
5 years 960.3
Extreme 960.3
1,925.5
10 years 461.3
Extreme 461.3
1,925.5
Manager TitleAgeSince
Chief Executive Officer 66 30/09/2012
Director of Finance/CFO 52 31/07/2021
Compliance Officer - 31/12/2022
Director TitleAgeSince
Director/Board Member 70 05/04/1999
Director/Board Member 66 30/09/2012
Director/Board Member 65 26/04/2017
Change 5-day change 1-year change 3-year change Capi.($)
+1.09%+6.59% - - 259B
+0.88%+6.38%+76.40%+126.75% 1,119B
+1.07%+3.80%+50.73%+62.78% 651B
+1.20%+6.21%+25.81%+78.74% 468B
+1.02%+5.77%+43.63%+48.43% 374B
+0.85%+4.07%+24.97%+40.58% 302B
+1.26%+6.81%+2.27%+14.41% 259B
+1.88%+5.81%+49.57%+70.53% 238B
+1.59%+2.09%-17.33%-52.62% 208B
+1.87%+5.61%+27.32%+91.38% 181B
Average +1.27%+4.97%+31.49%+53.44% 422.21B
Weighted average by Cap. +1.13%+5.09%+44.26%+72.65%

Financials

2026 *2027 *
Net sales 63.25B 54.18B 50.69B 46.4B 87.09B 6,051B 88.24B 599B 234B 3,040B 237B 232B 10,055B 66.84B 57.25B 53.57B 49.04B 92.03B 6,395B 93.25B 633B 247B 3,213B 251B 246B 10,626B
Net income 12.07B 10.34B 9.67B 8.86B 16.62B 1,155B 16.84B 114B 44.57B 580B 45.32B 44.34B 1,919B 13.72B 11.75B 10.99B 10.06B 18.89B 1,312B 19.13B 130B 50.65B 659B 51.5B 50.38B 2,180B
Net Debt 19.33B 16.55B 15.49B 14.18B 26.61B 1,849B 26.96B 183B 71.37B 929B 72.57B 70.99B 3,072B 11.65B 9.98B 9.34B 8.55B 16.04B 1,115B 16.26B 110B 43.03B 560B 43.75B 42.8B 1,852B
Logo AstraZeneca PLC
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (99.8%). Net sales break down by treatment area between oncology (42.6%), cardiovascular, renal and metabolic diseases (23%), respiratory and autoimmune diseases (14.7%), and other (19.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (0.2). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (22.9%), the United States (40.8%), Americas (6.1%) and Africa/Asia/Australia (22.8%).
Employees
96,100
Date Price Change Volume
21/08/26 SEK 1,577.50 +1.09% 591,907
20/08/26 SEK 1,560.50 +0.48% 622,527
19/08/26 SEK 1,553.00 +1.64% 599,022
18/08/26 SEK 1,528.00 +2.62% 513,903
17/08/26 SEK 1,489.00 +0.61% 833,287
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
166.83USD
Average target price
212.30USD
Spread / Average Target
+27.25%

Quarterly revenue - Rate of surprise